Protein C News and Research

RSS

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.

4 Feb 2010

New vaccine to prevent malaria infection shown promise to protect young children

A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients - young children - against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa.

4 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell.

3 Feb 2010

Bionanomotors can be used some day to move and manipulate molecules at nanoscale

A group of Marshall University researchers and their colleagues in Japan are conducting research that may lead to new ways to move or position single molecules-a necessary step if man someday hopes to build molecular machines or other devices capable of working at very small scales.

3 Feb 2010

Pall launches PallSep Biotech filtration system

Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.

From Pall Corporation 3 Feb 2010

Patients with high levels of proteinuria have increased risk of all-cause death

Patients with high levels of proteinuria (protein in urine) in addition to another marker of reduced kidney function had an associated increased risk of all-cause death, heart attack or progression to kidney failure, according to a study in the February 3 issue of JAMA.

3 Feb 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

MaxMuscleMass.com: Save up to 40% off the retail prices in body building supplement retail stores

MaxMuscleMass.com, an online body building supplement store, wants you to save up to 40% off the retail prices found in gyms and body building supplement retail stores.

3 Feb 2010

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

For the first time, researchers from the University of Pennsylvania School of Medicine have found that three different degenerative brain disorders are linked by a toxic form of the same protein. The protein, called Elk-1, was found in clumps of misshaped proteins that are the hallmarks of Parkinson's disease, Alzheimer's disease, and Huntington's disease.

3 Feb 2010

10 new kits available for fast and simple isolation of nucleic acids from blood, plasma and serum

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 10 new kits for the fast and simple isolation of nucleic acids from blood, plasma and serum, including circulating nucleic acids.

3 Feb 2010

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

The FDA on Monday said it's entering into a collaboration with the nonprofit group PATH "to speed creation of a pneumococcal vaccine for children in developing nations," United Press International reports (2/1).

3 Feb 2010

Study could provide potential therapeutic strategies for treating prostate cancer

Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, according to new data from researchers at UT Southwestern Medical Center.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

Research offers new hope for rare metabolic disorder

A research team led by biochemist Scott Garman at the University of Massachusetts Amherst has for the first time determined the mechanism of one of the cell's "recycling" enzymes, human alpha-galactosidase or alpha-GAL, as it breaks down substances in the lysosome, the cell's recycling center.

2 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Researchers identify 1.1M base pairs of DNA in soybean genome

In 2009, soybeans represented an almost $30 billion industry in the U.S. alone, making soybeans the second-most profitable crop next to corn. Worldwide, soybeans have been used in human foods and livestock feed for centuries and have been a key component in industrial products, such as plastics and soy biodiesel, an environmentally friendly fuel.

2 Feb 2010

Protein C News and Research

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

New vaccine to prevent malaria infection shown promise to protect young children

Phase 2a clinical trial results of VX-809 in patients with CF announced

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

Bionanomotors can be used some day to move and manipulate molecules at nanoscale

Pall launches PallSep Biotech filtration system

Patients with high levels of proteinuria have increased risk of all-cause death

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

MaxMuscleMass.com: Save up to 40% off the retail prices in body building supplement retail stores

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

10 new kits available for fast and simple isolation of nucleic acids from blood, plasma and serum

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

Study could provide potential therapeutic strategies for treating prostate cancer

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Research offers new hope for rare metabolic disorder

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

Cytheris broadens patent protection for recombinant human interleukin-7

Researchers identify 1.1M base pairs of DNA in soybean genome

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News